Dextera Surgical (NASDAQ: DXTR) and Thoratec (NASDAQ:THOR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings and institutional ownership.
This is a summary of recent recommendations and price targets for Dextera Surgical and Thoratec, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Dextera Surgical presently has a consensus target price of $0.75, suggesting a potential upside of 1,462.50%.
This table compares Dextera Surgical and Thoratec’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Dextera Surgical and Thoratec’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Dextera Surgical||$3.42 million||0.68||-$17.22 million||($1.77)||-0.03|
Thoratec has lower revenue, but higher earnings than Dextera Surgical. Dextera Surgical is trading at a lower price-to-earnings ratio than Thoratec, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
4.5% of Dextera Surgical shares are held by institutional investors. 10.4% of Dextera Surgical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Dextera Surgical Company Profile
Dextera Surgical Inc., formerly Cardica, Inc., designs and manufactures stapling devices that enable the advancement of minimally invasive surgical procedures. The Company is engaged in commercializing and developing its MicroCutter 5/80 stapler based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons. Its MicroCutter 5/80 is a commercially available cartridge-based microcutter device with approximately five millimeter shaft diameter, over 80 degrees of articulation, and an approximately 30 millimeter staple line cleared for specified indications for use in the United States, and in the European Union (EU) for a range of indications for use. It designs, manufactures and markets automated anastomotic systems used by surgeons to perform anastomoses during on- or off-pump coronary artery bypass graft procedures and these products include the C-Port xA system, the C-Port Flex A system and the PAS-Port Proximal Anastomosis System.
Thoratec Company Profile
Thoratec Corporation develops, manufactures and markets medical devices used for mechanical circulatory support for the treatment of heart failure patients. The Company’s products include ventricular assist devices (VADs), such as HeartMate II Left Ventricular Assist System (HeartMate II), HeartMate III Left Ventricular Assist System, Thoratec Paracorporeal Ventricular Assist Device (PVAD) and Thoratec Implantable Ventricular Assist Device (IVAD). For acute circulatory support, the Company’s product lines are CentriMag Acute Circulatory System (CentriMag) and for pediatric patients PediMag/PediVAS Acute Circulatory System (PediMag/PediVAS). HeartMate III, a centrifugal-flow, chronic, left ventricular assist system.
Receive News & Ratings for Dextera Surgical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dextera Surgical and related companies with MarketBeat.com's FREE daily email newsletter.